Gene expression meta-analysis identifies VDAC1 as a predictor of poor outcome in early stage non-small cell lung cancer

PLoS ONE

Volumn 6, Issue 1, 2011, Pages

  Grills, Claire ^a   Jithesh, Puthen V ^a   Blayney, Jaine ^a   Zhang, Shu Dong ^a   Fennell, Dean A ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CASEIN KINASE IALPHA; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN 1; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN A4; HEAT SHOCK PROTEIN A9; INITIATION FACTOR 2; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P53; RAF PROTEIN; RAS PROTEIN; UBIQUITIN CONJUGATING ENZYME E2; UBIQUITIN CONJUGATING ENZYME E2D; UNCLASSIFIED DRUG; VOLTAGE DEPENDENT ANION CHANNEL 1; VDAC1 PROTEIN, HUMAN;

AGE DISTRIBUTION; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; EARLY CANCER; GENE EXPRESSION PROFILING; HISTOPATHOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PRINCIPAL COMPONENT ANALYSIS; PROGNOSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN PROTEIN INTERACTION; RNA BINDING; SIGNAL TRANSDUCTION; SURVIVAL TIME; UBIQUITINATION; BREAST TUMOR; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; META ANALYSIS; MULTIPLE MYELOMA; PATHOLOGY; PREDICTIVE VALUE;

BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MULTIPLE MYELOMA; PREDICTIVE VALUE OF TESTS; PROGNOSIS; VOLTAGE-DEPENDENT ANION CHANNEL 1;

EID: 79551641146     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0014635     Document Type: Article

References (51)

1. Vallieres E (2007) Role of Adjuvant Systemic Therapy for Stage I NSCLC. Thoracic Surgery Clinics 17: 279-285.
2. Dakubo GD, Parr RL, Costello LC, Franklin RB, Thayer RE (2006) Altered metabolism and mitochondrial genome in prostate cancer. Journal of clinical pathology 59: 10-16.
3. Hoang JK, Hoagland LF, Coleman RE, Coan AD, Herndon JE, 2nd, et al. (2008) Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 26: 1459-1464.
4. Dooms C, van Baardwijk A, Verbeken E, van Suylen RJ, Stroobants S, et al. (2009) Association between 18F-fluoro-2-deoxy-D-glucose uptake values and tumor vitality: prognostic value of positron emission tomography in early-stage non-small cell lung cancer. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 4: 822-828.
5. Vander Heiden MG, Chandel NS, Schumacker PT, Thompson CB (1999) BclxL Prevents Cell Death following Growth Factor Withdrawal by Facilitating Mitochondrial ATP/ADP. Exchange Molecular Cell 3: 159-167.
6. Hiller S, Garces RG, Malia TJ, Orekhov VY, Colombini M, et al. (2008) Solution structure of the integral human membrane protein VDAC-1 in detergent micelles. Science (New York, NY) 321: 1206-1210.
7. Vander Heiden MG, Li XX, Gottleib E, Hill RB, Thompson CB, et al. (2001) Bcl-xL promotes the open configuration of the voltage-dependent anion channel and metabolite passage through the outer mitochondrial membrane. The Journal of biological chemistry 276: 19414-19419.
8. Madesh M, Hajnoczky G (2001) VDAC-dependent permeabilization of the outer mitochondrial membrane by superoxide induces rapid and massive cytochrome c release. The Journal of cell biology 155: 1003-1015.
9. Shimizu S, Narita M, Tsujimoto Y (1999) Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature 399: 483-487.
10. Roy SS, Madesh M, Davies E, Antonsson B, Danial N, et al. (2009) Bad targets the permeability transition pore independent of Bax or Bak to switch between Ca2+-dependent cell survival and death. Molecular cell 33: 377-388.
11. Cheng EH, Sheiko TV, Fisher JK, Craigen WJ, Korsmeyer SJ (2003) VDAC2 inhibits BAK activation and mitochondrial apoptosis. New York: Science 301: 513-517.
12. Baines CP, Kaiser RA, Sheiko T, Craigen WJ, Molkentin JD (2007) Voltagedependent anion channels are dispensable for mitochondrial-dependent cell death. Nature cell biology 9: 550-555.
13. Kumarswamy R, Chandna S (2009) Putative partners in Bax mediated cytochrome-c release: ANT, CypD, VDAC or none of them? Mitochondrion 9: 1-8.
14. Park J, Kim Y, Choi S, Koh H, Lee HE, et al. (2010) Drosophila Porin/VDAC Affects Mitochondrial Morphology. Plos One.
15. Sukumaran SK, Fu NY, Tin CB, Wan KF, Lee SS, et al. A soluble form of the pilus protein FimA targets the VDAC-hexokinase complex at mitochondria to suppress host cell apoptosis. Molecular cell 37: 768-783.
16. Arzoine L, Zilberberg N, Ben-Romano R, Shoshan-Barmatz V (2009) Voltagedependent anion channel 1-based peptides interact with hexokinase to prevent its anti-apoptotic activity. The Journal of biological chemistry 284: 3946-3955.
17. Pastorino JG, Shulga N, Hoek JB (2002) Mitochondrial binding of hexokinase II inhibits Bax-induced cytochrome c release and apoptosis. The Journal of biological chemistry 277: 7610-7618.
18. Galluzzi L, Kepp O, Tajeddine N, Kroemer G (2008) Disruption of the hexokinase-VDAC complex for tumor therapy. Oncogene 27: 4633-4635.
19. Pastorino JG, Hoek JB, Shulga N (2005) Activation of glycogen synthase kinase 3beta disrupts the binding of hexokinase II to mitochondria by phosphorylating voltage-dependent anion channel and potentiates chemotherapy-induced cytotoxicity. Cancer research 65: 10545-10554.
20. Majewski N, Nogueira V, Bhaskar P, Coy PE, Skeen JE, et al. (2004) Hexokinase-mitochondria interaction mediated by Akt is required to inhibit apoptosis in the presence or absence of Bax and Bak. Mol Cell 16: 819-830.
21. Koren I, Raviv Z, Shoshan-Barmatz V (2010) Downregulation of voltagedependent anion channel-1 expression by RNA interference prevents cancer cell growth in vivo. Cancer Biology Therapy 9.
22. Abu-Hamad S, Sivan S, Shoshan-Barmatz V (2006) The expression level of the voltage-dependent anion channel controls life and death of the cell. Proceedings of the National Academy of Sciences of the United States of America 103: 5787-5792.
23. Rho M, Kim J, Jee CD, Lee YM, Lee HE, et al. (2007) Expression of type 2 hexokinase and mitochondria-related genes in gastric carcinoma tissues and cell lines. Anticancer Res 27: 251-258.
24. Winton T, Livingston R, Johnson D, Rigas J, Johnston M, et al. (2005) Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 352: 2589-2597.
25. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, et al. (2004) Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350: 351-360.
26. Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, et al. (2006) Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 7: 719-727.
27. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, et al. (2000) Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 25: 25-29.
28. Yu H, Kim PM, Sprecher E, Trifonov V, Gerstein M (2007) The importance of bottlenecks in protein networks: correlation with gene essentiality and expression dynamics. PLoS computational biology 3: e59.
29. Boutros PC, Lau SK, Pintilie M, Liu N, Shepherd FA, et al. (2009) Prognostic gene signatures for non-small-cell lung cancer. Proc Natl Acad Sci U S A 106: 2824-2828.
30. Jiang H, Deng Y, Chen HS, Tao L, Sha Q, et al. (2004) Joint analysis of two microarray gene-expression data sets to select lung adenocarcinoma marker genes. BMC Bioinformatics 5: 81.
31. van Vliet MH, Reyal F, Horlings HM, van de Vijver MJ, Reinders MJ, et al. (2008) Pooling breast cancer datasets has a synergetic effect on classification performance and improves signature stability. BMC Genomics 9: 375.
32. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, et al. (2004) Largescale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci U S A 101: 9309-9314.
33. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102: 15545-15550.
34. Dundas SR, Lawrie LC, Rooney PH, Murray GI (2005) Mortalin is overexpressed by colorectal adenocarcinomas and correlates with poor survival. J Pathol 205: 74-81.
35. Kaul SC, Aida S, Yaguchi T, Kaur K, Wadhwa R (2005) Activation of wild type p53 function by its mortalin-binding, cytoplasmically localizing carboxyl terminus peptides. J Biol Chem 280: 39373-39379.
36. Wadhwa R, Yaguchi T, Hasan MK, Taira K, Kaul SC (2003) Mortalin-MPD (mevalonate pyrophosphate decarboxylase) interactions and their role in control of cellular proliferation. Biochem Biophys Res Commun 302: 735-742.
37. Kim MM, Wiederschain D, Kennedy D, Hansen E, Yuan ZM (2007) Modulation of p53 and MDM2 activity by novel interaction with Ras-GAP binding proteins (G3BP). Oncogene 26: 4209-4215.
38. Zhang HZ, Liu JG, Wei YP, Wu C, Cao YK, et al. (2007) Expression of G3BP and RhoC in esophageal squamous carcinoma and their effect on prognosis. World J Gastroenterol 13: 4126-4130.
39. Oc P, Rusch V, Talbot SG, Sarkaria I, Viale A, et al. (2004) Casein kinase II alpha subunit and C1-inhibitor are independent predictors of outcome in patients with squamous cell carcinoma of the lung. Clin Cancer Res 10: 5792-5803.
40. Zinszner H, Albalat R, Ron D (1994) A novel effector domain from the RNAbinding protein TLS or EWS is required for oncogenic transformation by CHOP. Genes Dev 8: 2513-2526.
41. Edgar R, Domrachev M, Lash AE (2002) Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 30: 207-210.
42. R_Development_Core_Team (2010) R: A Language and Environement for Statistical Computing. Vienna, Austria.
43. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, et al. (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5: R80.
44. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, et al. (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4: 249-264.
45. Ramasamy A, Mondry A, Holmes CC, Altman DG (2008) Key Issues in Conducting a Meta-Analysis of Gene Expression Microarray Datasets. Plos Medicine 5.
46. Saeed AI, Sharov V, White J, Li J, Liang W, et al. (2003) TM4: a free, opensource system for microarray data management and analysis. Biotechniques 34: 374-378.
47. Storey JD, Tibshirani R (2003) Statistical significance for genomewide studies. Proceedings of the National Academy of Sciences of the United States of America 100: 9440-9445.
48. Peri S, Navarro JD, Amanchy R, Kristiansen TZ, Jonnalagadda CK, et al. (2003) Development of human protein reference database as an initial platform for approaching systems biology in humans. Genome Res 13: 2363-2371.
49. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, et al. (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome research 13: 2498-2504.
50. Assenov Y, Ramirez F, Schelhorn SE, Lengauer T, Albrecht M (2008) Computing topological parameters of biological networks. Bioinformatics (Oxford, England) 24: 282-284.
51. Huang da W, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57.